Despite the high efficacy of TKIs in the treatment of BCR::ABL1-positive CML patients, a small portion of these patients demonstrate resistance and ultimately progress to the BP. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.